Completed

A Study of Galcanezumab (LY2951742) in Participants with Cluster Headache

I5Q-MC-CGAR - ClinicalTrials.gov - NCT02797951

The main purpose of this study is to assess the long-term safety and tolerability of galcanezumab administered up to once monthly in participants with episodic or chronic cluster headache who have completed study I5Q-MC-CGAL (NCT02397473) or study I5Q-MC-CGAM (NCT02438826).
How long will I be in the trial?
Your participation could last until approximately August 2020 and include monthly visits
Email
Completed

A Study of Galcanezumab (LY2951742) in Participants with Cluster Headache

I5Q-MC-CGAR - ClinicalTrials.gov - NCT02797951

The main purpose of this study is to assess the long-term safety and tolerability of galcanezumab administered up to once monthly in participants with episodic or chronic cluster headache who have completed study I5Q-MC-CGAL (NCT02397473) or study I5Q-MC-CGAM (NCT02438826).
How long will I be in the trial?
Your participation could last until approximately August 2020 and include monthly visits
Email

Key Requirements

Age :

18+

Sex:

All

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

18+

Sex

All

Participants must

Participant must have participated in and completed either study CGAL or study CGAM

Participant must be reliable to follow all study procedures, keep all study visits, and be compliant with study requirements - Female participant must not be pregnant or nursing

Participants must NOT

Participant must not be currently enrolled in or discontinued within the last 30 days from, a clinical trial involving any investigational drug or device (with the exception of study CGAL or study CGAM)

Trial Summary

Conditions the trial is for

Episodic Cluster Headache, Chronic Cluster Headache

What the trial is testing?

Galcanezumab (LY2951742)

Could I receive a Placebo?

no

Enrollment Goal

300

Trial Dates

July 2016 - January 2021

Trial Phase

3

Enter your postal code to find the nearest site

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

18+

Sex

All

Participants must

Participant must have participated in and completed either study CGAL or study CGAM

Participant must be reliable to follow all study procedures, keep all study visits, and be compliant with study requirements - Female participant must not be pregnant or nursing

Participants must NOT

Participant must not be currently enrolled in or discontinued within the last 30 days from, a clinical trial involving any investigational drug or device (with the exception of study CGAL or study CGAM)

Trial Summary

Conditions the trial is for

Episodic Cluster Headache, Chronic Cluster Headache

What the trial is testing?

Galcanezumab (LY2951742)

Could I receive a Placebo?

no

Enrollment Goal

300

Trial Dates

July 2016 - January 2021

Trial Phase

3

Not the right fit? Sign up to receive updates on new trials.

Trial Locations

Hide locations not currently recruiting

Enter your postal code to see sites near you

Resources

Clinical Trial Participation: What to Expect

Clinical Trial Participation: What to Expect

A clinical trial is a scientific study in people that helps to determine if and how a drug or therapy works. These can also be called clinical studies, or clinical research. Clinical research helps us answer specific questions about an investigational drug , such as: Is it effective? Is it more effective than another established treatment? Is it safe and/or what are its side effects?